Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Medtronic Microdebrider Turbinoplasty Is A Significantly More Effective, Long-Term Treatment Than Coblation® Radiofrequency For Nasal Obstruction
Medtronic (NYSE: MDT) announced that results of a study published in the February issue of the Laryngoscope were favorable toward the use of Medtronic"s Straightshot® M4 Microdebrider for powered inferior turbinoplasty. Written by Liu et al from Taipei Medical University, "Microdebrider-Assisted Versus Radiofrequency-Assisted Turbinoplasty," states that patients treated with Medtronic"s microdebrider experienced significantly better long-term outcomes than those who received treatment with a Coblation® radiofrequency device in what is the first three-year study directly comparing long-term efficacy of the two techniques.1

Computer Program To Detect, Measure Brain Tumors
The same techniques used to detect suspicious activity in airports, stadiums and other public places are now being used by the UCF researcher who invented them to find and measure potentially life-threatening brain tumors.
News of the day
Faculty Of 1000 Praised By Wellcome Trust
The Wellcome Trust has used Faculty of 1000 evaluations to monitor the success of their funding support.
Medical Devices

Science Magazine Spotlights 20 Years Of CF Research

An article in Science magazine this month highlights several promising new CF therapies, including VX-770 and VX-809 developed by Vertex Pharmaceuticals, as part of a look back at key moments in CF research since the discovery of the CF gene 20 years ago. The article notes the CF Foundation"s role in scientific discoveries: "The CF Foundation had been instrumental in funding the gene hunt and subsequent CF research, raising and investing tens of millions of dollars." In the piece, Francis Collins, former director of the National Human Genome Research Institute and co-discoverer of the CF gene, says the research community was initially skeptical about the Foundation"s focus on funding drug research to find a cure: "A lot of people thought that [CFF president] Bob Beall was going far out on a limb to put a lot of money into a strategy that was clearly risky." But now, following the Foundation"s investment of more than $75 million to develop VX-770 and VX-809, the "ò€¦two Vertex drugs are taking the CF world by storm." Cystic Fibrosis Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009